5731 results for "canc*"

in 22.74 milliseconds.

• 10x Single Cell Gene Expression Library SCRNA10X_SA_CHIP0163_002

  10x Single Cell Gene Expression library SCRNA10X_SA_CHIP0163_002 for Triple negative breast cancer sample SA609X7XB03510

  Dataset EGAD00001011218

• 10x Single Cell Gene Expression Library TENX048

  10x Single Cell Gene Expression library TENX048 for Triple negative breast cancer sample SA535X5XB02895

  Dataset EGAD00001011222

• 10x Single Cell Gene Expression Library SCRNA10X_SA_CHIP0146_006

  10x Single Cell Gene Expression library SCRNA10X_SA_CHIP0146_006 for Triple negative breast cancer sample SA535X6XB03099

  Dataset EGAD00001011223

• 10x Single Cell Gene Expression Library SCRNA10X_SA_CHIP0182_001

  10x Single Cell Gene Expression library SCRNA10X_SA_CHIP0182_001 for Triple negative breast cancer patient-derived xenograft SA535X7XB03304

  Dataset EGAD00001011225

• 10x Single Cell Gene Expression Library SCRNA10X_SA_CHIP0189_001

  10x Single Cell Gene Expression library SCRNA10X_SA_CHIP0189_001 for Triple negative breast cancer patient-derived xenograft SA535X7XB03448

  Dataset EGAD00001011226

• RNA-seq data from the tumor samples of head and neck cancer patients

  This dataset contains paired-end RNA sequencing data (2x50 bp) from the primary tumors and the recurrences/metastases of 6 head and neck cancer patients.

  Dataset EGAD00001011279

• Comparison of single/pooled CTCs and bulk exome sequencing

  Single cell technologies allow the interrogation of tumor heterogeneity, providing insights into tumor evolution and treatment resistance. To better understand whether circulating tumor cells (CTCs) could complement metastatic biopsies for tumor genomic profiling, we characterized 11 single CTCs and 10 pooled CTC samples at the mutational and copy number aberration (CNA) levels, and compared these results with matched synchronous tumor biopsies from 3 metastatic breast cancer patients with triple-negative (TNBC), HER2-positive and estrogen receptor-positive (ER+) tumors. Similar CNA profiles and the same patient-specific driver mutations were found in bulk tissue and CTCs for the HER2-positive and TNBC tumors, whereas different CNA profiles and driver mutations were identified for the ER+ tumor, which presented two distinct clones in CTCs defined by mutations in ESR1 Y537N and TP53, respectively. Furthermore, de novo mutational signatures derived from CTCs described patient-specific biological processes. These data suggest that tumor tissue and CTCs provide complementary clinically relevant information to map tumor heterogeneity and tumor evolution.

  Dataset EGAD00001009052

• Exome sequencing data from two small cell prostate cancer patients

  Exome sequencing data from two small cell prostate cancer patients - 4 cancer samples (FFPE) from Patient 1 collected at 3 different time points and 2 cancer samples (FFPE) from Patient 2 collected at 1 time point. Exonic DNA was enriched using the TruSeq Exome Kit (Illumina) and sequenced on the Illumina NextSeq 500 as 75bp paired end reads (total read length 150bp).

  Dataset EGAD00001011149

• Whole genome sequencing data of high-grade serous ovarian cancer samples (set 8a)

  Whole genome sequencing data of 26 high-grade serous carcinoma (HGSC) patients (87 samples) sequenced with MGISEQ-2000 and HiSeq X Ten.

  Dataset EGAD00001011304

• Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer

  Dataset consists of 216 samples, with each sample having a BAM, BAI and VCF file.

  Dataset EGAD00001011297